Trials / Completed
CompletedNCT03039686
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 6 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7239361 | Take RO7239361 subcutaneously on specified days over a 48 week blinded period |
| DRUG | Placebo for RO7239361 | Take placebo subcutaneously on specified days over a 48 week blinded period |
Timeline
- Start date
- 2017-07-06
- Primary completion
- 2020-04-28
- Completion
- 2020-04-28
- First posted
- 2017-02-01
- Last updated
- 2020-12-21
- Results posted
- 2020-12-21
Locations
44 sites across 13 countries: United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03039686. Inclusion in this directory is not an endorsement.